Breaking
Mifepristone Access Continues Under Supreme Court Hold as Planned Parenthood Responds to 5th Circuit RulingAlpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026Takeda's TAK-881 Shows Positive Phase 2/3 Results for Primary Immunodeficiency Disease Treatment
🇺🇸 FDA

Weight Loss

Page 1 • 1 item

Gain critical insights into the global weight loss drug market. Track pipeline advancements, regulatory approvals, and investment opportunities.

Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies
NewsObesity and Weight ManagementApr 29, 2026

Zealand Pharma's Survodutide Achieves 16.6% Weight Loss in Phase 3 Obesity Trial, Outperforming Current GLP-1 Therapies

Zealand Pharma announces survodutide achieved 16.6% weight loss in Phase 3 SYNCHRONIZE-1 trial, potentially exceeding Wegovy and Zepbound efficacy rates.

Dr. Sarah Mitchell